Diabetes mellitus type II: Review of oral treatment options

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue SUPPL. 1, 2010, Pages 21-30

  Ibrahim, Rana ^a  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

Author keywords

Alpha glycosidase inhibitors; Biguanides; Exenatide; Exubera; Short acting insulin secretagogues; Sitagliptin; Sulfonylureas; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; TRIACYLGLYCEROL; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOATING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPETITIVE INHIBITION; COST BENEFIT ANALYSIS; COUGHING; DIABETES CONTROL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; ENZYME ACTIVITY; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PATIENT COMPLIANCE; RASH; REVIEW; RHINORRHEA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 77953392434     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care29 (Suppl. 1):S4-42, 2006.
2. Bolen S, Feldman L, Vassy J, et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Ann Intern Med. 2007 July 16; [Epub ahead of print]
3. Carroll MF, Izard A, Riboni K, et al. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care. 2002 Dec;25(12):2147-52.
4. Nathan DM. Initial management of Glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002.
5. Inzucchi SE. Oral Antihyperglycemic therapy for type 2 diabetes. JAMA 287:360-372, 2002.
6. Colagiuri S, Cull CA, Holman RR, UKPDS Group: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? Diabetes Care 25:1410-1417, 2002.
7. Diabetes Prevention Program Research Group: Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002.
8. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus Nateglinide Monotherapy: a randomized, multicenter study. Diabetes Care 27:1265-1270, 2004.
9. Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-B: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093-2100, 2005.
10. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. Ann Intern Med 143:549-558, 2005.
11. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed dose combination compared with Uptitrated metformin alone in type 2 diabetes mellitus: a 24 week, multicenter, randomized, double blind, parallel group study. Clin Ther 27:1548-1561, 2005.
12. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76.
13. Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001 Nov;23(11):1792-823; discussion 1791.
14. Scheen AJ, Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab. 1998 Sep;24(4):311-20.
15. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as Monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006 Nov;49(11):2564-71.
16. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, Sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007 Jun 26; [Epub ahead of print].
17. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidas-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006 Oct;28(10):1556-68.
18. Herman GA, Bergman A, Yi B, et al. The Sitagliptin Study 012 Group Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Current medical research and opinion 2006 Oct;22(10):1939-47.
19. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005 Oct 18;143(8):128.
20. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323-332, 2005.
21. Wade N. Gene increases diabetes risk, scientists find. New York Times 16 Jan 2006:1.
22. Grant SF, Thorleifsson G, Reynisdottir L, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-3.
23. Lyssenko V, Almgren P, Anevski D, et al. Genetic prediction of future type 2 diabetes. PLOS Med 2005;2:e345.
24. Diabetes statistics. Bethesda, Md.: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, NIDDK, 1995; NIH publication no. 96-3926.
25. http://www.texasdiabetescouncil.org: Glycemic Control Algorithm For Type 2 Diabetes Mellitus In Children And Adults/Accessed on July 25, 2007.
26. Smilev D, Umpierrez G. Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with type 2 diabetes. Expert Opin Pharmacother. 2007 Jun;8(9):1353-64.
27. Pratley R, et al. Efficacy and safety of Vildagliptin in the elderly: Pooled analysis of 5 monotherapy studies. Presented at EASD 17-21 September 2007.
28. Garber A, et al. Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM). Presented at ADA, 22-26 June 2007; (Abstract 501-P).
29. Nelson P, et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007 Aug ;9(4): 317-26.